arecoline and paclitaxel

arecoline has been researched along with paclitaxel in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Cristofaro, I; Di Bari, M; Español, AJ; Salem, A; Sales, ME; Sanchez, Y; Tata, AM	1

Other Studies

1 other study(ies) available for arecoline and paclitaxel

Article	Year
The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype. PloS one, 2020, Volume: 15, Issue:9 Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Arecoline; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbachol; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholinergic Agonists; Down-Regulation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Neovascularization, Pathologic; Paclitaxel; Receptor, Muscarinic M2; RNA, Small Interfering; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2020

Article

Year

The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.

PloS one, 2020, Volume: 15, Issue:9

Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Arecoline; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbachol; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholinergic Agonists; Down-Regulation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Neovascularization, Pathologic; Paclitaxel; Receptor, Muscarinic M2; RNA, Small Interfering; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2020